Drug Profile

OXU 003

Alternative Names: OXU-003

Latest Information Update: 03 Apr 2025

Price :

$50 ^*

Note:

Adis is an information provider. We do not sell or distribute actual drugs.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

Originator Oxular
Developer Regeneron Pharmaceuticals
Class Antineoplastics
Mechanism of Action Undefined mechanism

Orphan Drug Status

Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

Yes - Retinoblastoma
New Molecular Entity Yes

Highest Development Phases

Discontinued Retinoblastoma

Most Recent Events

15 Feb 2023 Discontinued - Preclinical for Retinoblastoma in USA (unspecified route) (Oxular Limited, February 2023)
20 Jul 2022 Oxular plans to submit IND application for Retinoblastoma in 2023 (Oxular pipeline, July 2022)
12 Oct 2020 Oxular Limited plans phase II trial for Retinoblastoma in 2024 (Oxular pipeline, July 2022)

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com